Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis

  • Louise E. Crowley
  • , Ellen Jenkins
  • , Akalanka Ranasinghe
  • , Tamara Naneishvili
  • , Mengshi Yuan
  • , Khalid Hussain
  • , Francisco Leyva-Leon
  • , Anjali Crawshaw
  • , William E. Moody

Research output: Contribution to journalArticlepeer-review

1   Link opens in a new tab Citation (SciVal)
2 Downloads (Pure)

Abstract

Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.
Original languageEnglish
Article number102265
JournalJournal of Nuclear Cardiology
Volume50
Early online date9 Jun 2025
DOIs
Publication statusPublished - Aug 2025

Bibliographical note

Copyright © 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Fingerprint

Dive into the research topics of 'Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis'. Together they form a unique fingerprint.

Cite this